Luke Schenck

603 total citations
29 papers, 419 citations indexed

About

Luke Schenck is a scholar working on Pharmaceutical Science, Molecular Biology and Materials Chemistry. According to data from OpenAlex, Luke Schenck has authored 29 papers receiving a total of 419 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pharmaceutical Science, 9 papers in Molecular Biology and 9 papers in Materials Chemistry. Recurrent topics in Luke Schenck's work include Drug Solubulity and Delivery Systems (22 papers), Protein purification and stability (9 papers) and Advanced Drug Delivery Systems (9 papers). Luke Schenck is often cited by papers focused on Drug Solubulity and Delivery Systems (22 papers), Protein purification and stability (9 papers) and Advanced Drug Delivery Systems (9 papers). Luke Schenck collaborates with scholars based in United States, Singapore and United Kingdom. Luke Schenck's co-authors include Athanas Koynov, Aaron Cote, R.J. Plank, Ivan Lee, Yongchao Su, Neil A. Strotman, Amanda K. P. Mann, Chad Dalton, Michael Lowinger and Xingyu Lu and has published in prestigious journals such as International Journal of Pharmaceutics, Pharmaceutical Research and Journal of Pharmaceutical Sciences.

In The Last Decade

Luke Schenck

29 papers receiving 410 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Luke Schenck United States 12 257 159 71 65 58 29 419
Catherine Boissier Sweden 11 158 0.6× 83 0.5× 57 0.8× 43 0.7× 34 0.6× 21 379
Vibha Puri India 11 228 0.9× 144 0.9× 52 0.7× 58 0.9× 56 1.0× 15 366
Niels Erik Olesen Denmark 12 349 1.4× 247 1.6× 160 2.3× 102 1.6× 66 1.1× 17 567
Scott V. Jermain United States 10 444 1.7× 225 1.4× 124 1.7× 105 1.6× 50 0.9× 10 596
Tze Ning Hiew United States 11 250 1.0× 142 0.9× 47 0.7× 58 0.9× 53 0.9× 19 335
Chandra Vemavarapu United States 8 354 1.4× 208 1.3× 115 1.6× 106 1.6× 72 1.2× 8 565
Eero Suihko Finland 12 278 1.1× 104 0.7× 59 0.8× 55 0.8× 57 1.0× 20 519
Aaron Cote United States 10 92 0.4× 380 2.4× 114 1.6× 53 0.8× 40 0.7× 19 543
Jari Pajander Denmark 12 210 0.8× 110 0.7× 76 1.1× 48 0.7× 101 1.7× 24 399
Martin Wunderlich Germany 9 278 1.1× 137 0.9× 55 0.8× 142 2.2× 61 1.1× 11 435

Countries citing papers authored by Luke Schenck

Since Specialization
Citations

This map shows the geographic impact of Luke Schenck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luke Schenck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luke Schenck more than expected).

Fields of papers citing papers by Luke Schenck

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luke Schenck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luke Schenck. The network helps show where Luke Schenck may publish in the future.

Co-authorship network of co-authors of Luke Schenck

This figure shows the co-authorship network connecting the top 25 collaborators of Luke Schenck. A scholar is included among the top collaborators of Luke Schenck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luke Schenck. Luke Schenck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Koynov, Athanas, Jameson R. Bothe, Luke Schenck, et al.. (2025). A Precipitation-Based Process to Generate a Solid Formulation of a Therapeutic Monoclonal Antibody: An Alternative to Lyophilization. MDPI (MDPI AG). 2(1). 2–2. 1 indexed citations
2.
Karde, Vikram, et al.. (2024). Process-Induced Crystal Surface Anisotropy and the Impact on the Powder Properties of Odanacatib. Pharmaceutics. 16(7). 883–883. 3 indexed citations
3.
4.
Schenck, Luke, et al.. (2024). Enhancing the Acidity of Polymers for Improved Stabilization of Amorphous Solid Dispersions: Protonation of Weakly Basic Compounds. ACS Applied Polymer Materials. 6(3). 1592–1598. 5 indexed citations
5.
Hiew, Tze Ning, Prapti Kafle, Dmitry Zemlyanov, et al.. (2024). The importance of surface composition and wettability on the dissolution performance of high drug loading amorphous dispersion formulations. Journal of Pharmaceutical Sciences. 114(1). 289–303. 7 indexed citations
6.
Axnanda, Stephanus, et al.. (2024). Impact of route of particle engineering on dissolution performance of posaconazole. International Journal of Pharmaceutics. 669. 125025–125025. 2 indexed citations
7.
Manghnani, Purnima Naresh, Luke Schenck, Saif A. Khan, & Patrick S. Doyle. (2023). Templated Reactive Crystallization of Active Pharmaceutical Ingredient in Hydrogel Microparticles Enabling Robust Drug Product Processing. Journal of Pharmaceutical Sciences. 112(8). 2115–2123. 1 indexed citations
8.
Schenck, Luke, et al.. (2023). Structural Modifications of Polyethylenimine to Control Drug Loading and Release Characteristics of Amorphous Solid Dispersions. Molecular Pharmaceutics. 20(3). 1779–1787. 9 indexed citations
9.
Saboo, Sugandha, et al.. (2023). Evaluating Spray Drying and Co-Precipitation as Manufacturing Processes for Amorphous Solid Dispersions of a Low Tg API. Journal of Pharmaceutical Sciences. 112(8). 2087–2096. 4 indexed citations
10.
Schenck, Luke, et al.. (2023). A Commentary on Co-Processed API as a Promising Approach to Improve Sustainability for the Pharmaceutical Industry. Journal of Pharmaceutical Sciences. 113(2). 306–313. 5 indexed citations
11.
Nie, Haichen, Chad Dalton, James D. Ormes, et al.. (2022). High Bulk-Density Amorphous Dispersions to Enable Direct Compression of Reduced Tablet Size Amorphous Dosage Units. Journal of Pharmaceutical Sciences. 112(8). 2037–2045. 8 indexed citations
12.
Iuzzolino, Luca, et al.. (2022). Dissolution Behavior of Weakly Basic Pharmaceuticals from Amorphous Dispersions Stabilized by a Poly(dimethylaminoethyl Methacrylate) Copolymer. Molecular Pharmaceutics. 19(9). 3304–3313. 9 indexed citations
13.
Hiew, Tze Ning, Sugandha Saboo, Dmitry Zemlyanov, et al.. (2022). Improving Dissolution Performance and Drug Loading of Amorphous Dispersions Through a Hierarchical Particle Approach. Journal of Pharmaceutical Sciences. 112(8). 2057–2068. 11 indexed citations
14.
15.
Schenck, Luke, Xiujuan Jia, Wes Schafer, et al.. (2021). A Co-Processed API Approach for a Shear Sensitive Compound Affording Improved Chemical Stability and Streamlined Drug Product Processing. Journal of Pharmaceutical Sciences. 110(9). 3238–3245. 14 indexed citations
16.
Schenck, Luke, et al.. (2021). Hierarchical Particle Approach for Co-Precipitated Amorphous Solid Dispersions for Use in Preclinical In Vivo Studies. Pharmaceutics. 13(7). 1034–1034. 14 indexed citations
17.
Schenck, Luke, Deniz Erdemir, Jeremy M. Merritt, et al.. (2020). Recent Advances in Co-processed APIs and Proposals for Enabling Commercialization of These Transformative Technologies. Molecular Pharmaceutics. 17(7). 2232–2244. 44 indexed citations
18.
Schenck, Luke, Amanda K. P. Mann, Zhen Liu, et al.. (2019). Building a better particle: Leveraging physicochemical understanding of amorphous solid dispersions and a hierarchical particle approach for improved delivery at high drug loadings. International Journal of Pharmaceutics. 559. 147–155. 20 indexed citations
19.
Mann, Amanda K. P., Luke Schenck, Athanas Koynov, et al.. (2017). Producing Amorphous Solid Dispersions via Co-Precipitation and Spray Drying: Impact to Physicochemical and Biopharmaceutical Properties. Journal of Pharmaceutical Sciences. 107(1). 183–191. 43 indexed citations
20.
Schenck, Luke & R.J. Plank. (2007). Impact milling of pharmaceutical agglomerates in the wet and dry states. International Journal of Pharmaceutics. 348(1-2). 18–26. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Catherine Boissier Breakdown of academic impact, for papers by Vibha Puri Breakdown of academic impact, for papers by Niels Erik Olesen Breakdown of academic impact, for papers by Scott V. Jermain Breakdown of academic impact, for papers by Tze Ning Hiew Breakdown of academic impact, for papers by Chandra Vemavarapu Breakdown of academic impact, for papers by Eero Suihko Breakdown of academic impact, for papers by Aaron Cote Breakdown of academic impact, for papers by Jari Pajander Breakdown of academic impact, for papers by Martin Wunderlich
Rankless by CCL
2026